| Entry |
|
|---|
| Name |
Mavelertinib (USAN/INN) |
|---|
| Formula |
C18H22FN9O2
|
|---|
| Exact mass |
415.1880
|
|---|
| Mol weight |
415.43
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D11368 Mavelertinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR
D11368 Mavelertinib (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 30
1 N5x N 13.7571 -18.0632
2 C8y C 14.9654 -18.7703
3 N5x N 14.9684 -20.1510
4 C8y C 13.7279 -20.8848
5 C8y C 12.5196 -20.1777
6 C8y C 12.5519 -18.7366
7 N4y N 11.2022 -18.2712
8 C8x C 10.3138 -19.3734
9 N5x N 11.1434 -20.5889
10 N1b N 13.7309 -22.2654
11 N1y N 16.1762 -18.0975
12 C1a C 10.8151 -16.9257
13 C1x C 17.3292 -18.8916
14 C1y C 18.4407 -18.0404
15 C1y C 17.9747 -16.7202
16 C1x C 16.5752 -16.7555
17 X F 19.7564 -18.4320
18 N1b N 18.7846 -15.5442
19 C8y C 12.5114 -22.9666
20 C8x C 11.1828 -22.5791
21 N4y N 10.4011 -23.7232
22 N5x N 11.2476 -24.8202
23 C8y C 12.5525 -24.3541
24 C1a C 9.0304 -23.7630
25 O2a O 13.6959 -25.1350
26 C1a C 14.9792 -24.5182
27 C5a C 20.1554 -15.5134
28 O5a O 20.8957 -16.7311
29 C2b C 20.8179 -14.3042
30 C2a C 22.1900 -14.2730
BOND 33
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 4 10 1
12 2 11 1
13 7 12 1
14 11 13 1
15 13 14 1
16 14 15 1
17 15 16 1
18 11 16 1
19 14 17 1 #Down
20 15 18 1 #Up
21 10 19 1
22 19 20 2
23 20 21 1
24 21 22 1
25 22 23 2
26 19 23 1
27 21 24 1
28 23 25 1
29 25 26 1
30 18 27 1
31 27 28 2
32 27 29 1
33 29 30 2
|
|---|
